share_log

Avenue Therapeutics | UPLOAD: Others

Avenue Therapeutics | UPLOAD: Others

Avenue Therapeutics | UPLOAD:其他
美股SEC公告 ·  05/08 12:46

Moomoo AI 已提取核心信息

Avenue Therapeutics, Inc. has been informed by the Division of Corporation Finance Office of Life Sciences that the United States Securities and Exchange Commission (SEC) will not review the company's Registration Statement on Form S-3, which was filed on May 6, 2024. The SEC's communication, dated May 8, 2024, was addressed to Dr. Alexandra MacLean, CEO of Avenue Therapeutics. The SEC also reminded the company of its responsibility for the accuracy and adequacy of disclosures, irrespective of the SEC's review process. The SEC provided contact information for any further questions and referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process.
Avenue Therapeutics, Inc. has been informed by the Division of Corporation Finance Office of Life Sciences that the United States Securities and Exchange Commission (SEC) will not review the company's Registration Statement on Form S-3, which was filed on May 6, 2024. The SEC's communication, dated May 8, 2024, was addressed to Dr. Alexandra MacLean, CEO of Avenue Therapeutics. The SEC also reminded the company of its responsibility for the accuracy and adequacy of disclosures, irrespective of the SEC's review process. The SEC provided contact information for any further questions and referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process.
公司已收到生命科学办公室的企业融资部的通知,美国证券交易所(SEC)将不会审核于2024年5月6日提交的S-3表格的申请文件,此信件发出日期是2024年5月8日,收信人为Avenue Therapeutics的CEO Alexandra MacLean女士。SEC还提醒公司不论SEC审核结果如何,披露信息的准确性和充分性都由公司负责。SEC给出了进一步咨询的联系方式,并提及了规则460和461,这些规则涉及请求加快注册流程的事项。
公司已收到生命科学办公室的企业融资部的通知,美国证券交易所(SEC)将不会审核于2024年5月6日提交的S-3表格的申请文件,此信件发出日期是2024年5月8日,收信人为Avenue Therapeutics的CEO Alexandra MacLean女士。SEC还提醒公司不论SEC审核结果如何,披露信息的准确性和充分性都由公司负责。SEC给出了进一步咨询的联系方式,并提及了规则460和461,这些规则涉及请求加快注册流程的事项。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息